Julie Vose, MD, MBA and Owen A. O’Connor, MD, PhD
In this video, “T-Cell Lymphoma Genomics in Practice”, Julie Vose, MD and Owen O’Connor, MD, PhD discuss the potential for genomics in guiding treatment.
Genomics have identified many actionable targets and are providing rationale for studies of novel therapies and synergistic combinations (e.g., romidepsin and azacitidine). Today, blood specimens are crucial to define molecular signatures in clinical trials. However, in contrast to the more common B-cell lymphomas, the rarity of T-cell lymphomas favors development of broad, overarching strategies rather than molecular subset-directed therapies. Nevertheless, in the future, genomic methods, such as NGS (next generation sequencing), may help to define patients who are most likely to respond to treatment.